Andrea Tan
Stock Analyst at Goldman Sachs
(2.11)
# 1,238
Out of 4,479 analysts
33
Total ratings
37.93%
Success rate
-2.34%
Average return
Main Sectors:
Top Industries:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Initiates: Neutral | $31 | $25.22 | +22.92% | 1 | Jun 5, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Sell | $3 → $2 | $2.99 | -33.11% | 3 | Jun 5, 2024 | |
| INSM Insmed | Maintains: Buy | $49 → $74 | $64.50 | +14.73% | 5 | May 29, 2024 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $27 → $23 | $2.93 | +684.98% | 4 | May 16, 2024 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $19 → $21 | $7.73 | +171.67% | 4 | Feb 29, 2024 | |
| TARS Tarsus Pharmaceuticals | Maintains: Neutral | $19 → $30 | $27.55 | +8.89% | 2 | Feb 29, 2024 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $50 → $44 | $13.46 | +226.89% | 4 | Feb 27, 2024 | |
| KOD Kodiak Sciences | Reinstates: Sell | $2 | $2.24 | -10.71% | 1 | Dec 11, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $160 | $177.61 | -9.91% | 1 | Nov 20, 2023 | |
| ABCL AbCellera Biologics | Maintains: Buy | $27 → $24 | $2.77 | +766.43% | 2 | Aug 4, 2023 | |
| FATE Fate Therapeutics | Maintains: Sell | $10 → $4 | $3.22 | +24.22% | 2 | Jan 9, 2023 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $178 → $375 | $271.67 | +38.04% | 1 | Dec 20, 2022 | |
| VERV Verve Therapeutics | Initiates: Sell | $13 | $5.00 | +160.00% | 1 | Dec 15, 2022 | |
| VOR Vor Biopharma | Maintains: Neutral | $6 → $4 | $0.91 | +337.64% | 2 | May 24, 2022 |
Arrowhead Pharmaceuticals
Jun 5, 2024
Initiates: Neutral
Price Target: $31
Current: $25.22
Upside: +22.92%
Relmada Therapeutics
Jun 5, 2024
Downgrades: Sell
Price Target: $3 → $2
Current: $2.99
Upside: -33.11%
Insmed
May 29, 2024
Maintains: Buy
Price Target: $49 → $74
Current: $64.50
Upside: +14.73%
Sagimet Biosciences
May 16, 2024
Maintains: Buy
Price Target: $27 → $23
Current: $2.93
Upside: +684.98%
Iovance Biotherapeutics
Feb 29, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $7.73
Upside: +171.67%
Tarsus Pharmaceuticals
Feb 29, 2024
Maintains: Neutral
Price Target: $19 → $30
Current: $27.55
Upside: +8.89%
Day One Biopharmaceuticals
Feb 27, 2024
Maintains: Buy
Price Target: $50 → $44
Current: $13.46
Upside: +226.89%
Kodiak Sciences
Dec 11, 2023
Reinstates: Sell
Price Target: $2
Current: $2.24
Upside: -10.71%
Krystal Biotech
Nov 20, 2023
Initiates: Buy
Price Target: $160
Current: $177.61
Upside: -9.91%
AbCellera Biologics
Aug 4, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $2.77
Upside: +766.43%
Fate Therapeutics
Jan 9, 2023
Maintains: Sell
Price Target: $10 → $4
Current: $3.22
Upside: +24.22%
Madrigal Pharmaceuticals
Dec 20, 2022
Maintains: Buy
Price Target: $178 → $375
Current: $271.67
Upside: +38.04%
Verve Therapeutics
Dec 15, 2022
Initiates: Sell
Price Target: $13
Current: $5.00
Upside: +160.00%
Vor Biopharma
May 24, 2022
Maintains: Neutral
Price Target: $6 → $4
Current: $0.91
Upside: +337.64%